Trinity Biotech (TRIB) Cash from Operations (2009 - 2024)

Trinity Biotech has disclosed Cash from Operations across 16 years of filings, most recently posting $3.6 million for Q4 2024.

• In Q4 2024, Cash from Operations rose 1055.81% year-over-year to $3.6 million; the TTM figure through Dec 2024 stood at -$4.0 million (up 65.53% YoY), while the FY2025 annual figure was -$5.9 million, down 41.47% from the prior year.
• Cash from Operations came in at $3.6 million for Q4 2024 at Trinity Biotech, up from -$3.6 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $14.8 million in Q4 2020 to a low of -$4.7 million in Q3 2023.
• Average Cash from Operations over 5 years is $1.1 million, with a median of $642000.0 recorded in 2021.
• Year-over-year, Cash from Operations slumped 786.89% in 2023 and soared 1055.81% in 2024.
• Over 5 years, Cash from Operations stood at $14.8 million in 2020, then tumbled by 73.66% to $3.9 million in 2021, then sank by 41.51% to $2.3 million in 2022, then tumbled by 86.45% to $310000.0 in 2023, then soared by 1055.81% to $3.6 million in 2024.
• Per Business Quant data, the three most recent Cash from Operations figures were $3.6 million in Q4 2024, -$3.6 million in Q3 2024, and -$1.1 million in Q2 2024.